Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma
Open Access
- 1 March 2015
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 109 (3) , 329-338
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
This publication has 14 references indexed in Scilit:
- Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthmaRespiratory Research, 2014
- Tiotropium in Asthma Poorly Controlled with Standard Combination TherapyNew England Journal of Medicine, 2012
- Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: A randomised trialRespiratory Medicine, 2012
- Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 yearsEuropean Respiratory Review, 2012
- 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroidsEuropean Respiratory Journal, 2012
- Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthmaJournal of Allergy and Clinical Immunology, 2011
- Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trialJournal of Allergy and Clinical Immunology, 2011
- Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2010
- Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE studyBMC Pulmonary Medicine, 2006
- Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveysJournal of Allergy and Clinical Immunology, 2004